Quoin Pharmaceuticals Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $QNRX in the last 30 days.
See all $QNRX insider activity →BTIG initiated coverage of Quoin Pharmaceuticals with a Buy rating and $14 price target, implying a 211.1% upside from the Oct 9 close of $4.50. The firm cited strong clinical data for QRX003 in treating Netherton Syndrome and a significant market opportunity exceeding $3 billion.
Quoin Pharmaceuticals (QNRX) announced a paper on QRX003 was accepted by Dermatology and Therapy, citing interim Phase 2/3 data where 4/6 patients met the primary IGA endpoint. Compassionate-use updates showed improvements with no treatment-related adverse events reported.
Quoin Pharmaceuticals (QNRX) announced a peer-reviewed paper on QRX003, its investigational treatment for Netherton Syndrome, was accepted by Dermatology and Therapy. The paper details QRX003's mechanism and a case report of a pediatric patient's positive response. Quoin also reported interim Phase 2/3 study results, with 66.7% of participants achieving the primary endpoint. QRX003 has received Orphan Drug and Fast Track designations.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning QNRX (Quoin Pharmaceuticals Ltd.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent QNRX coverage spans financial news, corporate actions and insider activity.
Analyst upgrade and high price target likely drive buying pressure.
Positive interim data may lift the stock as investors anticipate further efficacy and potential regulatory filings.
Positive clinical validation may boost investor sentiment.
Positive trial data plus fresh capital raise should lift the stock, especially after pre‑market price jump.
The designation is a positive regulatory milestone that could accelerate development and boost the stock.
AlphAI scores every news story that mentions QNRX with an AI model for sentiment and relevance, and aggregates insider trades from Quoin Pharmaceuticals Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BTIG initiated coverage of Quoin Pharmaceuticals with a Buy rating and $14 price target, implying a 211.1% upside from the Oct 9 close of $4.50. The firm cited strong clinical data for QRX003 in treating Netherton Syndrome and a significant market opportunity exceeding $3 billion.
1 min readQuoin Pharmaceuticals (QNRX) announced a paper on QRX003 was accepted by Dermatology and Therapy, citing interim Phase 2/3 data where 4/6 patients met the primary IGA endpoint. Compassionate-use updates showed improvements with no treatment-related adverse events reported.
2 min readQuoin Pharmaceuticals (QNRX) announced a peer-reviewed paper on QRX003, its investigational treatment for Netherton Syndrome, was accepted by Dermatology and Therapy. The paper details QRX003's mechanism and a case report of a pediatric patient's positive response. Quoin also reported interim Phase 2/3 study results, with 66.7% of participants achieving the primary endpoint. QRX003 has received Orphan Drug and Fast Track designations.
2 min readChange Agents Corp. (CHGA) launched a subsidiary for AI-enabled counter-drone tech and added a retired general to its advisory board. Quoin Pharmaceuticals (QNRX) reported positive Phase 2/3 trial data for QRX003 and raised $50M. Myseum.AI (MYSE) partnered with Fujifilm for print-on-demand products. Linkers Industries (LNKS) increased its stake in LPW Electronics, boosting its Thai operations.
3 min readQuoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome – First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy – Second Fast Track Designation Granted to QRX003, in Addition to Netherto
2 min readQuoin Pharmaceuticals (QNRX) filed a Form D notice for a private securities offering under Rule 506(b). The deal may bring in tens of millions, with securities including equity and options. The company declined to disclose revenue range.
1 min readQuoin Pharmaceuticals (QNRX) announced FDA granted Rare Pediatric Disease Designation for QRX003, its treatment for Peeling Skin Syndrome. This is the second such designation for QRX003, following one for Netherton Syndrome. If approved, Quoin may receive a Priority Review Voucher. The company plans to initiate a Phase 2 study in 2H 2026, enrolling up to 12 patients. There are currently no approved treatments for Peeling Skin Syndrome.
2 min readQuoin Pharmaceuticals (QNRX) executives bought shares at $4.88 each, now at $6.51. CuriosityStream (CURI) CEO bought shares near 52-week low. FTC Solar (FTCI) director increased stake. Motorsport Games (MSGM) saw insider buying. Airbnb (ABNB) strategy officer sold $13.45M in shares. ORTHOPEDIATRICS (KIDS) saw major share sales. Oruka Therapeutics (ORKA) CEO sold $6.89M in shares. Aura Minerals (AUGO) director had net buying. Caterpillar (CAT) CEO sold $26.21M in shares.
3 min readCarter Denise P. (Chief Operating Officer) purchased 20,490 shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $4.88 on 2026-08-31.
1 min readMyers Michael (Chief Executive Officer) purchased 20,490 shares of Quoin Pharmaceuticals, Ltd. (QNRX) at $4.88 on 2026-08-31.
1 min read
